Last Updated : May 20, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort ascending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| NuvaRing | Etonogestrel/ethinyl estradiol | Contraceptive, ring | List with clinical criteria and/or conditions | Complete | ||
| Evra | Norgelestromin/ethinyl estradiol | Contraceptive, patch | Do not list | Complete | ||
| Slynd | drospirenone | Contraceptive, oral | Reimburse with clinical criteria and/or conditions | Active | ||
| Yasmin | Drospirenone /ethinyl estradiol | Contraceptive, oral | List | Complete | ||
| Relistor | Methylnaltrexone bromide | Constipation, Opioid-induced | Do not list | Complete | ||
| Resotran | Prucalopride | Constipation, chronic | Do not list | Complete | ||
| Trecondyv | treosulfan | Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) (pediatric) | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Trecondyv | treosulfan | Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) | Reimburse with clinical criteria and/or conditions | Active | ||
| Keytruda | pembrolizumab | Colorectal cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Dificid | Fidaxomicin | Clostridium difficile infection | Do not list at the submitted price | Complete |
Last Updated : May 20, 2024